Abstract: Parallel co-production process for the production of methanol and urea product from a hydrocarbon containing feed-stock by means of primary and secondary reforming, intermediary methanol and ammonia formation and conversion of the ammonia to urea product and catalytic oxidation of methanol to formaldehyde.

Abstract: The present disclosure relates to the formation of terephthalate esters.

Abstract: The present disclosure relates to a method for recycling a taurine mother liquor, which includes: adding a base to the taurine mother liquor, heating to a first temperature, carrying out a hydrolysis reaction, removing ammonia produced, and evaporating and concentrating the ammonia-removed solution to obtain an alkali metal hydroxyethyl sulfonate solution. When applying the method provided by the present disclosure for the recycling of the taurine mother liquor, the taurine mother liquor can be further converted into the alkali metal hydroxyethyl sulfonate solution, impurities are removed from the obtained alkali metal hydroxyethyl sulfonate solution, the impurity-removed alkali metal hydroxyethyl sulfonate solution is concentrated and crystallized, and the alkali metal hydroxyethyl sulfonate is separated out.

Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

Abstract: The invention relates to a method for producing a urea solution with a target urea concentration using water flows recovered from the urea production process. At least part of the water flows recovered from the urea production process are only partially purified to produce the urea solution. The invention further relates to a process condensate treatment plant to implement the method for producing a urea solution with a target urea concentration, and a urea production plant comprising such process condensate treatment plant.

Abstract: A compound of Formula (IX):

Abstract: Provided is a method of preparing L-homoserine, the method including contacting an L-homoserine derivative with a solid acid catalyst.

Abstract: The present invention relates to a process for preparing a (2-cyclopentenyl)acetate ester compound of general formula (2) as described herein, the process comprising: subjecting a haloacetaldehyde alkyl 2-cyclopentenyl acetal compound of general formula (1) as described herein to a dehydrohalogenation reaction in the presence of a base, followed by a rearrangement reaction to form the (2-cyclopentenyl)acetate ester compound of general formula (2). The present invention also relates to a process for preparing a (2-cyclopentenyl)acetic acid compound of general formula (3) as described herein, the process comprising hydrolyzing the (2-cyclopentenyl)acetate ester compound of general formula (2) to form the (2-cyclopentenyl)acetic acid compound of general formula (3). The present invention also relates to a haloacetaldehyde alkyl 2-cyclopentenyl acetal compound of general formula (1) as described herein.

Abstract: A full continuous-flow preparation method of L-carnitine, including: mixing chlorine gas and a diketene solution via a first micromixer followed by transportation to a first microchannel reactor for continuous chlorination and esterification reaction to obtain 4-chloroacetoacetate; feeding the 4-chloroacetoacetate and a reductase to a second micromixer and a second microchannel reactor in sequence for continuous catalytic reaction to obtain (R)-4-chloro-3-hydroxybutyrate; simultaneously transporting the (R)-4-chloro-3-hydroxybutyrate and a trimethylamine solution to a third micromixer and a third microchannel reactor for continuous substitution and hydrolysis reaction; and subjecting the reaction mixture to desalination and concentration to obtain the L-carnitine.

Abstract: The present invention provides a method for producing an amino acid aminoalkyl ester or an inorganic acid salt thereof by reacting a compound represented by general formula (I) shown below or a compound represented by general formula (III) shown below, or a salt thereof, and at least one compound selected from the group consisting of compounds represented by general formula (IV-I) shown below, compounds represented by general formula (IV-II) shown below, compounds represented by general formula (IV-III) shown below and compounds represented by general formula (IV-IV) shown below, or an inorganic acid salt thereof.

Abstract: This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Cathepsin K (CatK), and to a method of inhibiting cathepsin activity, comprising administering a compound or formulation comprising a compound according to the invention.

Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.

Abstract: The invention relates to a process for preparing fatty acid chlorides. In a subsequent step, the fatty acid chlorides can be used to prepare N-acyl amino acid salts. The process comprises the formation of a fatty acid chloride in an amine catalyzed reaction of a fatty acid with phosphorous trichloride, thionyl chloride or phosgene, preferably thionyl chloride. The process for preparing N-acyl amino acid salts further comprises the reaction of the fatty acid chloride with an amino acid or an amino ethane sulfonic acid.

Abstract: The invention relates to a use of a fluorination gas, and the elemental fluorine (F2) is present in a high concentration, for example, in a concentration of elemental fluorine (F2), especially of equal to much higher than 15 or even 20% by volume, and to a process for the manufacture of a fluorinated compound by direct fluorination employing a fluorination gas, wherein the elemental fluorine (F2) is present in a high concentration. The process of the invention is directed to the manufacture of a fluorinated compound, for the exception of fluorinated benzene, by direct fluorination. Especially the invention is of interest in the preparation of fluorinated organic compounds, final products and as well intermediates, for usage in agro-, pharma-, electronics-, catalyst, solvent and other functional chemical applications. The fluorination process of the invention may be performed batch-wise or in a continuous manner.

Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.

Abstract: The present disclosure provides a composition for treating urea particles under ambient atmospheric conditions, a method for treating urea particles with the composition and to a fertiliser treated with the composition. The composition functions to reduce moisture induced agglomeration of treated urea particles compared to moisture induced agglomeration of untreated urea particles. The composition includes a solvent and a mixture of a first and a second aliphatic compound, each compound respectively comprising a selected C8-C14 saturated straight chain hydrocarbon a selected C15-C19 saturated straight chain hydrocarbon.

Abstract: Provided are monomers useful for dental materials that include a compound in which a core and a specific terminal group are bonded to each other directly or via a linking group, wherein the core is a C1-200 polyvalent organic group having a valence of not less than 3 containing an oxygen atom or a nitrogen atom in which an atom bonded to the terminal group or the linking group is the oxygen atom or the nitrogen atom; the terminal group is a specific (meth)acryloyl group-containing group, a (meth)acryloyl group, a C1-20 hydrocarbon group or a hydrogen atom, and the terminal group needs to meet specific requirements; and the linking group is a specific divalent group, and when the compound contains a plurality of linking groups, the linking groups may be the same as or different from each other. Compositions, dental materials and kits are also provided.

Abstract: The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. The field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection/readout, and also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI.

Abstract: The disclosure provides recording materials including aromatic substituted alkane-core derivatized monomers and polymers for use in volume Bragg gratings, including, but not limited to, volume Bragg gratings for holography applications. Several structures are disclosed, including Formula I. When used in Bragg gratings applications, the monomers and polymers disclosed lead to materials with higher refractive index, low birefringence, and high transparency. The disclosed derivatized monomers and polymers can be used in any volume Bragg gratings materials, including two-stage polymer materials where a matrix is cured in a first step, and then the volume Bragg grating is written by way of a second curing step of a monomer.

Abstract: The application relates to a process for the synthesis of organic sulfonic acid salts of amino acid esters comprising the steps of (i) reacting at least one lactam with at least 3 carbon atoms in the lactam ring with at least one organic sulfonic acid in an aqueous solution, (ii) esterification of the organic sulfonic amino acid salt of step (i) with at least one alcohol with at least 8 carbon atoms comprising at least one hydroxyl group, (iii) optionally removal of water and/or removal of excess alcohol of step (ii). The application also relates to organic sulfonic acid salts of amino acid esters of the general formula (I).